But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Ever wondered if Merck’s current share price actually reflects its real worth? You’re not alone, and uncovering value can make all the difference for your portfolio. Merck’s stock has jumped 18.4% ...

Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new ...

Finally, Merck is an excellent dividend stock. It offers a juicy forward yield of 3.2% and has increased its payouts by 93.8% ...

On December 4, 2025, Merck & Co., Inc. completed a significant financial maneuver by closing an underwritten public offering of various notes totaling $7 billion. This strategic move is expected to ...

Investing.com -- Alteogen shares plunged as much as 12% on the Kosdaq exchange on Friday, marking the stock’s biggest drop in more than a year, after its partner Merck faced a legal setback in Germany ...

Merck (MRK) has quietly pulled ahead of many pharma peers, with the stock climbing about 22% over the past month and 20% in ...

Global stocks fell after Bitcoin crashed below $86,000 and Japans BOJ signaled a possible rate hike. S&P 500 futures dropped ...

The start of a historically strong month on Wall Street saw stocks falling as traders shunned riskier corners of the market ...

The economics of warfare have shifted. Now $500-700 drones are taking out multi-million-dollar assets (tanks, radars etc.). Legacy missile-based countermeasures are too expensive to deploy against ...